To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

HIV DRUGS

TODAY'S HEADLINES

FDA approves drug for pregnant women with HIV

FDA recently approved an expansion to the prescribing information for darunavir (Prezista), to treat pregnant women with HIV. Most HIV drugs are not indicated for use during pregnancy. Read more

New weight management pill available soon

FDA recently approved the New Drug Application (NDA) for lorcaserin HCl CIV extended-release 20 mg tablets (Belviq XR), a once-a-day dosing option for chronic weight management. Read more

CONTINUING PHARMACY EDUCATION

Expanding vaccination rates through pharmacist-initiated patient identification and assessment

This month's CE activity, "Expanding vaccination rates through pharmacist-initiated patient identification and assessment," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about current vaccine recommendations so that they can identify adolescent and adult patients who may need vaccinations. Readers will also gain knowledge about where to obtain information about current vaccine recommendations.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Top 4 ways US is combating opioid epidemic

Expanding access to buprenorphine, a medication to treat opioid use disorder, is one of several new actions announced by Health and Human Services (HHS) to combat the opioid epidemic. Find out the other new guidelines from HHS. Read more

July 27, 2016

Related Articles

Top 7 facts to know about new HIV drug

First binge eating disorder drug approved

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us